Engineering Human Cardiac Muscle Patch Constructs for Prevention of Post-infarction LV Remodeling

Vahid Serpooshan, Emory University
L Wang, University of Alabama Birmingham
J Zhang, University of Alabama Birmingham

Journal Title: FRONTIERS IN CARDIOVASCULAR MEDICINE
Volume: Volume 8, Number
Publisher: FRONTIERS MEDIA SA | 2021-02-26, Pages 621781-621781
Type of Work: Article
Publisher DOI: 10.3389/fcvm.2021.621781
Permanent URL: https://pid.emory.edu/ark:/25593/vsz4w

Final published version: http://dx.doi.org/10.3389/fcvm.2021.621781

Accessed November 16, 2022 11:06 AM EST
Engineering Human Cardiac Muscle Patch Constructs for Prevention of Post-infarction LV Remodeling

Lu Wang¹, Vahid Serpooshan²,³,⁴ and Jianyi Zhang*¹

¹ Department of Biomedical Engineering, School of Medicine and School of Engineering, University of Alabama at Birmingham, Birmingham, AL, United States, ² Department of Biomedical Engineering, Emory University School of Medicine and Georgia Institute of Technology, Atlanta, GA, United States, ³ Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, United States, ⁴ Children’s Healthcare of Atlanta, Atlanta, GA, United States

Tissue engineering combines principles of engineering and biology to generate living tissue equivalents for drug testing, disease modeling, and regenerative medicine. As techniques for reprogramming human somatic cells into induced pluripotent stem cells (iPSCs) and subsequently differentiating them into cardiomyocytes and other cardiac cells have become increasingly efficient, progress toward the development of engineered human cardiac muscle patch (hCMP) and heart tissue analogs has accelerated. A few pilot clinical studies in patients with post-infarction LV remodeling have been already approved. Conventional methods for hCMP fabrication include suspending cells within scaffolds, consisting of biocompatible materials, or growing two-dimensional sheets that can be stacked to form multilayered constructs. More recently, advanced technologies, such as micropatterning and three-dimensional bioprinting, have enabled fabrication of hCMP architectures at unprecedented spatiotemporal resolution. However, the studies working on various hCMP-based strategies for in vivo tissue repair face several major obstacles, including the inadequate scalability for clinical applications, poor integration and engraftment rate, and the lack of functional vasculature. Here, we review many of the recent advancements and key concerns in cardiac tissue engineering, focusing primarily on the production of hCMPs at clinical/industrial scales that are suitable for administration to patients with myocardial disease. The wide variety of cardiac cell types and sources that are applicable to hCMP biomanufacturing are elaborated. Finally, some of the key challenges remaining in the field and potential future directions to address these obstacles are discussed.

Keywords: tissue engineering, cardiac patch, myocardium, heart failure, myocardial infarction, regenerative medicine, cardiac regeneration and remodeling

INTRODUCTION

Despite advancements in preventive medicine, cardiovascular disease (CVD) remains a leading cause of morbidity and mortality worldwide (1, 2) with estimated 17.9 million people died of cardiovascular disease in 2016, accounting for 31% of all deaths globally (3). The molecular and cellular basis for progressive heart failure is the result of the inability of damaged and apoptotic myocytes to be replaced. The regenerative capacity of mammalian hearts declines rapidly after birth, and <1% of cardiomyocytes (CMs) in the hearts of adult humans are replaced each year (4);
thus, myocardial injury leads to adverse cardiac remodeling and fibrosis as the injured myocardium is replaced by fibrotic scar tissue (5, 6). The only available procedure for end-stage patients is whole-heart transplantation which is restricted by an inadequate supply of donors. Therefore, alternative strategies for limiting post-injury cardiac remodeling and remuscularizing the damaged myocardium are urgently needed (7, 8). Administration of exogenous stem cells was initially considered a promising approach (9). The cells were expected to differentiate into CMs after transplantation (10, 11); however, the results from subsequent preclinical and clinical studies indicated that the benefits were only marginal and likely attributable to the cells’ paracrine activity, because the proportion of cells that were retained and survived at the site of injury (i.e., the engraftment rate) was drastically low (12, 13).

Tissue engineering combines the principles of engineering and life sciences to better understand the structure-function relationships in normal and pathological tissues and to generate living tissue equivalents for drug testing (14, 15), disease modeling (16–18), and regenerative medicine (6, 19, 20; Figure 1). In the cardiovascular field, the first proof-of-concept study was conducted in 1997, when embryonic chick CMs were suspended in collagen solution, and the mixture subsequently solidified and contracted coherently between two glass tubes (21). With the emergence of techniques for reprogramming human somatic cells into induced pluripotent stem cells (iPSCs) and differentiating them into CMs (22) and other cardiac cells, the field has progressed to the development of engineered human cardiac muscle patch (hCMP) constructs (6). These engineered patch constructs are often associated with higher rates of engraftment and appear to support the injured myocardium more effectively than transplanted cells (2, 23). Nevertheless, vascularization of the hCMP (either during manufacture or via the infiltration of native vessels after transplantation) is not extensive and efficient enough to support the high metabolic demand of the heart (13, 24). Consequently, the thickness/dimensions of most hCMPS are limited to just a few hundreds of micrometers (13, 25). In this review, we discuss many of the most recent advancements in cardiac tissue engineering, with a primary focus on techniques for generating thicker and more integrative hCMP systems.

**Cell Types and Sources for hCMP Fabrication**

CMs are the fundamental contractile units of the myocardium and occupy 70–85% of myocardial volume in adult mammals (26); thus, many investigations of cell therapy have been conducted with CMs alone, either as dissociated cells or contiguous sheets (27, 28). However, hCMPS are designed to comprehensively recapitulate the physical structure and signaling pathways present in native heart tissue (13, 29) and, therefore, are typically composed of multiple cardiac cell types,
Cell sources for cardiac tissue engineering. A variety of cell types can be used in tissue engineered cardiac constructs, including cardiomyocytes derived from iPSCs or isolated from rodent hearts, cardiac vascular cells and fibroblasts, different progenitor and stem cells, and various spheroids. iPSC, induced pluripotent cells; ECs, endothelial cells; SMCs, smooth muscle cells; FBs, fibroblasts; MSCs, mesenchymal stem cells; BM-cells, bone marrow-cells; PSCs, pluripotent stem cells; CPCs, cardiac progenitor cells.

including CMs, endothelial cells (ECs), smooth muscle cells (SMCs), and cardiac fibroblasts (6, 26, 30). Other cell types or clusters of multiple cell types (e.g., progenitor cells and spheroids) have also been incorporated into cardiac patches and evaluated in preclinical models of myocardial injury (Figure 2).

Cardiomyocytes (CMs)
Healthy adult human CMs were largely unavailable for early hCMP studies due to scarcity of healthy heart donors and their non-proliferative phenotype. Thus, most of what we have explored and learned about the structural and functional properties of engineered cardiac tissues was initially investigated in experiments using primary rodent CMs (31). Pioneering work with fetal CMs from 15-day-old mouse embryos demonstrated that the cells were engrafted and survived after administration into the mouse hearts (32). Rhythmically contracting hydrogels were generated by plating neonatal rat heart cells on collagen, which enabled researchers to study how factors, such as cell density and collagen concentration, influenced contractile activity (33) and to demonstrate that these cellular constructs generated electrocardiography (ECG)-like potentials (34). Subsequent studies confirmed that patches composed of fetal rat ventricular cells and gelatin could survive and continue to contract when implanted subcutaneously in the adult rat legs. The engineered graft formed junctions with native heart cells when delivered to the scarred region of cryoinjured hearts, but whether the treatment could improve cardiac function remained uncertain (35). Patches consisting of fetal rat cardiac cells suspended in an alginate scaffold were among the first to preserve measures of cardiac function and impede adverse cardiac remodeling when administered to infarcted rat hearts (36).

Embryonic stem cells (ESCs) and iPSCs are the most readily available sources of human-lineage CMs, because they can proliferate indefinitely and be differentiated into cells of different lineages (37). The first human vascularized, contracting hCMP was generated by combining CMs and ECs derived from human ESCs with mouse embryonic fibroblasts in porous sponges composed of 50% poly-l-lactic acid (PLLA) and 50% polylactic-glycolic acid (PLGA) (38). Experiments in both rodent (19, 39, 40) and swine (23) models of myocardial injury suggest that iPSC-based hCMPs are associated with higher levels of cell survival and engraftment than those associated with iPSC-based cell injection, and that the cells’ paracrine activity can be modestly beneficial. Both ESC- and iPSC-derived CMs are, however, structurally and functionally more similar to fetal or neonatal cells than to the adult mature CMs. This could hinder downstream applications of hCMs composed of immature PSC-CMs. The electrical immaturity of PSC-CMs may induce ventricular arrhythmias as demonstrated in non-human primate models, raising a safety concern for clinical translation (41, 42). Therefore, various methods for improving stem cell-derived CM maturity before transplantation, including electrical stimulation, and treatment with neurohormonal factors, have been frequent topics of research (43–46). hCMP maturation can be influenced by the purity of the initial CM population, as evidenced by increases in conduction velocity and contractile force (44). Further, mechanical conditioning of cardiac patches has been shown effective in maturation and functional improvement of encapsulated CMs. For instance, hCMs consisting of a collagen matrix and CMs differentiated from mouse ESCs, more closely
Cardiac Vascular Cells and Fibroblasts

Cardiac ECs and SMCs not only promote the vascularization and survival of transplanted hCMPs but are also key mediators of the signaling mechanisms that regulate CM activity (23, 48, 49). Cardiac fibroblasts can further improve CM survival by remodeling the extracellular matrix (ECM) and releasing cytoprotective paracrine factors (6, 9, 50–52). Except for providing a reliable source of CMs, hiPSCs demonstrate great potential in offering vascular cells and fibroblasts. Robust protocols for differentiating hiPSCs to ECs (53), SMCs (50), and cardiac fibroblasts (54, 55) have been established. The inclusion of ECs and stromal cells, combined with uniaxial mechanical stimulation during manufacturing, has been shown to improve the hCMP maturity (56). However, early protocols for hiPSC-EC differentiation are not efficient and the phenotype of generated hiPSC-ECs remain rather unstable. Refined EC differentiation protocols, utilizing spatiotemporal 3D environments, have prolonged the maintenance of EC phenotype to up to 4 weeks (57). With deeper insights into the signaling pathways affecting cardiac cell differentiation, novel protocols for EC and SMC differentiation have yielded efficiencies exceeding 80% within 6-day time periods (58). Great efforts have also been devoted to deriving arterial EC from hiPSC, which demonstrated arterial-specific functional characteristics unlike generic ECs, thus offering reliable cell sources for hCMP (59). Cardiac fibroblasts have been successfully differentiated from hPSCs, which resembled native cardiac fibroblasts in morphology, gene expression, and proliferation. Notably, hPSC-derived cardiac fibroblasts could generate three-dimensional (3D) ECM scaffolds and their co-culture with hiPSC-CMs could increase action potential propagation rate compared to co-culture with dermal fibroblasts (60). Despite development of refined protocols for generation of vascular cells and fibroblasts of arterial lineage, the optimal combination and proportion of cell types for recapitulating the complex 3D environment of native heart tissue continues to be an active area of research (52, 61–64).

Pluripotent Stem Cells

Pluripotent Stem Cells (PSCs), including ESCs and iPSCs, have revolutionized the field of cardiac tissue engineering by providing a platform of unlimited numbers and types of cells due to their ability to self-renew indefinitely and the plasticity to differentiate into any type of cells (6, 45). ESCs were initially derived from inner cell mass of developing blastocyst (65), thus raising ethical issues due to destruction of fertilized human embryos. ESCs could also be collected via parthenogenesis which alleviates the ethical issues (66). In contrast, iPSCs were initially reprogrammed from somatic cells via overexpression of four transcription factors, Oct4 (octamer-binding transcription factor 4), Sox2 (sex determining region Y-box 2), Klf4 (KLF family of transcription factor 4), and Myc (67). Different combinations of transcription factors, such as Oct4, Sox2, Nanog, and Lin28 (68) or only Oct4 and Sox2 (69) can be also used to generate iPSCs. Despite the controversy on immunogenicity of autologous iPSCs (70–73), devoid of ethical issues qualifies them as one of the most promising cell sources for cardiac tissue engineering.

PSCs have revolutionized biomedicine by providing robust platforms for regenerative medicine, drug screening, and disease modeling, all requiring reproducible and efficient protocols for differentiating PSCs to CMs. Initially, contractile CMs were spontaneously differentiated from hESCs in 3D embryoid bodies (EBs) with low efficiencies (74–76). These early protocols suffered from line-to-line variability, inclusion of undefined components, and heterogeneous EB sizes (77, 78). To advance the yield and purity of CM differentiation protocols, in-depth knowledge of the pathways involved in embryonic heart developments was utilized to optimize the process. CM differentiation stages typically involve early mesendoderm priming, cardiac progenitor specification, and differentiation into CM subtypes such as ventricular and atrial like phenotypes (79–81). Modulation of TGFβ signaling superfamily via serial application of activin A and bone morphogenetic protein 4 (BMP4) yielded >30% CMs (82); manipulation of Activin/Nodal and BMP4 signaling pathways could efficiently induce cardiac mesoderm, resulting >60% CMs in mouse PSCs and >50% in human PSCs (83). Robust CM differentiation protocols have been developed by mimicking biphasic pattern of WNT pathway with chemical compounds. Temporal modulating Wnt pathway via GSK inhibitor CHIR99021 and Wnt inhibitor IWP2 generated 80–98% CMs (84). Suspension culture in stirred tank bioreactors was utilized to upscale hPSC expansion and lineage differentiation (85, 86). Efforts have been made to develop suspension culture based hPSC-CM production with good manufacturing practice standards (79, 87). Pioneering works of hCMP with PSC-CMs have laid foundation for optimization of manufacturing methods and demonstrated beneficial efficacy after transplantation into animal models with higher engraftment and survival rate than those associated with iPSC-based cell injection (38, 47, 56). Notably, hCMP fabrication typically incorporates PSC-derived cardiac cells with refined protocols to differentiate PSC into ECs, SMCs, and fibroblasts which benefit hCMPs via pre-vascularization and secretion of ECM proteins (50, 52).

Progenitor Cells

The results from early clinical trials suggested that the modest benefits associated with transplanted bone marrow-derived cells and cardiac progenitor cells (CPCs) occurred via the cells’ paracrine activity, rather than by directly repairing the damaged heart tissue (30). Nevertheless, bone marrow mesenchymal stem cells (MSCs) have been suspended in 3D hydrogels and tested in a rat model of myocardial infarction (MI) (88). The development of a program for generating human ESC-derived CPCs under Good Manufacturing Practice (GMP) conditions (89) led to the first clinical trial of hESC-CPCs, in which the cells were administered by suspending them in fibrin and suturing the patch to the surface of the infarcted heart. Heart function improved symptomatically and no safety concerns were observed 3 months after transplantation (90). Further research was conducted to investigate the efficacy of ESC-derived cardiovascular progenitors administered in a fibrin patch in six patients with severe ischemic left ventricular dysfunction. Results demonstrated uneventful

Wang et al. Engineering Human Cardiac Muscle Patch

Frontiers in Cardiovascular Medicine | www.frontiersin.org 4 February 2021 | Volume 8 | Article 621781

resembled native myocardial tissue after undergoing 7 days of in vitro cyclic stretching (47).
Main manufacturing methods for cardiovascular tissue engineering. Human cardiac muscle patch (hCMP) constructs can be fabricated using a variety of bioengineering methods, including cell sheets, scaffolds, decellularized heart tissues, 3D (bio)printing, and cell-free patches.
spontaneously (110). Furthermore, the cells of adjacent layers form connections that facilitate communication between layers, including gap junctions, which are required for electrical coupling (111). Although, constructs composed of more than four cellular layers are typically resistant to vascularization, the vascularity of fabricated cell sheets can be improved by the inclusion of stromal cells or omentum during manufacture (112, 113). Further, CM survival and contractile function were significantly improved when iPSC-CM sheets were covered with an omentum flap after transplantation into infarcted pig hearts (114–116). However, transplanted cell sheets tend to remain electromechanically isolated from the native myocardium, which suggests that the observed benefits likely occur primarily through the activation of paracrine mechanisms (117). Clinical trials utilizing cell sheets of skeletal myoblast demonstrated safety and feasibility with no complications, paving the way for further therapeutic efficacy studies (118, 119). Notably, the Japanese health ministry recently approved the use of iPSC-derived CM sheets in a small study of patients with heart disease, which represents only the second clinical application of iPSC-derived cells (115, 120).

Extracellular Matrix

The biomaterials used in scaffold-based hCMePs (121) are designed to mimic the native cardiac ECM which consists of a highly specialized, 3D network of structural (e.g., collagen) and non-structural (e.g., glycoproteins, proteoglycans, and glycosaminoglycans) proteins that support cardiac function (122, 123). The patch biomaterial is aimed to provide the architecture for cell attachment and cell-cell or cell-matrix interactions (122, 124) and facilitate the coordinated transmission of electrical and mechanical signals (9). Therefore, several design criteria for scaffold biomaterials have been established. Biocompatibility of materials is critical to minimize immunogenicity and cytotoxicity, while promoting cell attachment, differentiation and proliferation (30, 125). Biodegradability is another important aspect of scaffolding biomaterials, allowing the material to degrade at an appropriate rate while new ECM proteins are being synthesized (106, 126). Biomechanical and biophysical properties of materials such as stiffness, elasticity, and porosity enable effective electromechanical coupling of cardiac scaffolds and facilitate mass transport within the constructs (9, 94, 127, 128). Toward that goal, strategies utilizing natural hydrogels (e.g., collagen, fibrin, and Matrigel), synthetic polymers (e.g., polyglycolic acid, polycaprolactone, polylactic acid, and poly-D, L-lactic-co-glycolic acid), or nanofibrous materials as scaffolds have been attempted (9, 129–135). Natural materials have the advantages of promoting cell attachment and viability without cytotoxicity. Nevertheless, physical properties of natural materials could vary from batch to batch and source to source. Immunogenicity is also a concern for xeno-transplantation. Synthetic materials could be designed to precisely control mechanical properties and degradation rate, thus inducing minimal immunogenicity. However, the novel composition of synthetic materials often struggles to fully support cell adhesion and survival. Various scaffold architectures and geometries that have been tested include cylindrical constructs, which typically contain only small numbers of cells, and therefore, are usually scaled to much larger hCMePs at clinically relevant dimensions (2 cm × 4 cm × 1.25 mm) (23). Other structures used are various rodent-sized ventricular organoids (9).

Decellularized Heart Tissues

The role of the ECM in cardiac differentiation, organization, and vascularization is well-established by many studies with decellularized heart tissues (136). The ECM from decellularized human ventricles is shown to induce CM gene expression in human CPCs and MSCs. Further, human umbilical vein ECs formed endocardial and vascular linings in these constructs, and fully differentiated human CMs aggregated into muscular bundles with mature calcium dynamics and electrical coupling (137). Whole rat hearts have been also decellularized, seeded with cardiac and endothelial cells, and perfused in bioreactors, demonstrating macroscopic contractions after only 4 days of culture. By day 8 in culture, the recellularized hearts displayed pumping function in response to electrical stimulation, equivalent to about 2% of adult rat hearts (138). Even in the absence of seeded cells, application of a decellularized porcine myocardial tissue resulted in significant improvements in cardiac functional parameters when evaluated in a rat model of MI, and the patch was vascularized by cells that had migrated from the native tissues (139).

3D Bioprinting—Additive Biomanufacturing

3D bioprinting technologies utilize CAD modeling to guide the assembly of living cells and other biological materials into large-scale tissue and organ analogs with precisely controlled, native-like architectures (92, 140–143). In an early work, tissue printing technology was utilized to generate a construct composed of human cardiac-derived CPCs and alginate. The printed construct remained committed to cardiac lineage with high viability after culturing for 7 days (144). In subsequent studies, human CM progenitor cells were bioprinted into a matrix of hyaluronic acid and gelatin to form a patch with six perpendicularly printed layers and a total surface area of 4 cm². When evaluated in a murine MI model, the patch improved measures of cardiac function and prevented remodeling. The expression of cardiac and vascular differentiation markers increased during the 4-week follow-up period (145). Scaffold-free bioprinted hCMePs have been also generated by loading spheroids, one-by-one, onto an array of needles, allowing them to fuse, and then removing the hCMeP and culturing it until the needle holes were filled in with surrounding tissue. The construct remained engrafed and displayed evidence of vascularization 1 week after implantation into the infarcted rat hearts (104). A more recent, customized device has been developed that can load an entire layer of spheroids onto the needle array simultaneously, which will substantially reduce the time required to print larger engineered constructs (146).

The resolution of traditional bioprinting techniques cannot accommodate the structural details that facilitate interactions with individual cells. To address this limitation, a more advanced technique, multiphoton-excited (MPE) 3D bioprinting, has emerged, allowing the control of the architecture of
photoactive polymers to resolutions of <1 µm and, consequently, reproducing the structural features of the ECM with high fidelity (147). MPE 3D-printed hCMs composed of iPSC-derived CMs, ECs, and SMCs in a photoactive gelatin scaffold began generating calcium transients and beating synchronously within 1 day post-manufacturing. The printed patches were associated with significant improvements in cardiac function (left ventricular ejection fraction and fractional shortening), infarct size, apoptosis, vascularity, and cell proliferation when tested in mice with surgically induced MI (62). Photoactivated 3D bioprinting has also been conducted with a bioink containing both ECM proteins and hiPSCs to generate two-chambered structures with both inlet and outlet vessels. The hiPSCs proliferated and differentiated into mature cardiac cells in situ to form a living pump with contiguous walls of human cardiac muscle that mimicked the chambers and large vessels of a native heart (148).

Cell-Free Cardiac Patches
Cell- and tissue-based treatments will likely require specialized methods of storage and transportation to maintain cell viability (149). Since most of the benefits associated with transplanted cells and engineered tissues appear to evolve from the paracrine factors produced by the cells, rather than the cells themselves (150), strategies that exploit the regenerative activity of these paracrine factors may be more easily translated to the clinics. The three primary categories of secreted, biologically active cellular products are growth factors (typically proteins that function as signaling molecules), non-coding RNA (short, single-stranded oligonucleotides that regulate gene expression), and extracellular vesicles of endosomal origin (151). Artificial cardiac patches have been manufactured by encapsulating the factors secreted by cardiac stromal cells in PLGA and then embedding the capsule in decellularized porcine myocardium. Applying these factor-laden patches to the infarcted hearts of both immunocompetent rats and pigs resulted in reduced scarring and improved cardiac function, without inducing an immune response (152). In other works, the controlled release of miRNAs from injected hydrogels has shown improvement in cardiac function in infarcted mouse hearts (153). Further, hydrogel patches containing the extracellular vesicles produced by human iPSC-CMs reduced infarct size and cardiac hypertrophy in a rat MI model (154). Collectively, these results suggest that the controlled release of paracrine factors from cell-free patches or injected biomaterials may be a feasible alternative approach to transplanted hCMs for the treatment of myocardial disease.

Increasing hCMP Thickness/Dimensions
Despite substantial improvements in the components and protocols used for hCMP manufacturing, few studies have been conducted with constructs of clinically relevant size. Even patches with comparatively large surface areas (e.g., 8 cm²) are relatively thin (1.25 mm) (23), with inability of direct perfusion limiting thickness of hCMP to 1–2 mm (155, 156). Thus, production methods continue to be optimized and enhanced for the development of larger and thicker hCMP constructs. The inability to engineer and maintain thick and viable hCMP jeopardizes the clinical applications due to their inability to mimic characteristics of native myocardium, such as generating adult-like forces and action potentials (157, 158). In practice, hCMP thickness is often limited by the diffusion of oxygen and nutrients from the vasculature after transplantation, which requires CMs to be within 100–200 µm distance from the capillaries (159). Diffusion can be facilitated by including molecular crystals (e.g., sucrose) in the matrix solution and leaching them out after the matrix solidifies to increase the porosity of the scaffold (160). However, hCMCs of clinically relevant thicknesses require formation of a dense internal vascular network that couples with the native circulation after transplantation (9, 157). Vascularization can be increased by including combinations of vascular and other cell types (ECs, SMCs, and/or fibroblasts) (23, 62, 161) during manufacturing and/or via the nanoparticle-mediated (151) extended release of pro-angiogenic factors [e.g., vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), and the Wnt activator CHIR99021; (162, 163)], which can promote infiltration of the native circulatory system. Further, the spatial orientation of the vascular network can be controlled with more technologically advanced fabrication methods (e.g., micropatterning and 3D bioprinting) to enhance the mass transport and perfusion ([164]; Figure 4).

Layer-By-Layer Assembly
In theory, the layer-by-layer assembly technique enables hCMCs of any desired thickness to be generated simply by stacking the required number of individual CM sheets. However, since the individual layers of multilayered hCMCs are grown in isolation before assembly, intercellular connectivity is likely to be greater between cells within the same layer than between the cells of adjacent layers. Techniques for enhancing the formation of physical and electromechanical connections between layers include the use of graphene oxide (GO)-based thin films, which improved not only adhesion but also electrical coupling, maturation and cell organization (165), as well as the Tissue-Velcro platform, in which cardiac cells are cultured on 2D cell meshes that incorporate a microfabricated hook-and-loop system. After layering, the hooks and loops of adjacent layers interlocked and the hCMC contracted in response to electrical stimulation (166). The vascularization of multilayered hCMCs can be promoted by sandwiching vascular cells between the CM layers (167, 168). Coherent vascular networks have been generated in stacked hCMCs by using resected tissue as a vascular bed. When the resected vasculature was overlaid with sheets of cardiac cells (including ECs), connected to a bioreactor, and perfused with culture medium, ECs in the cardiac-cell layers connected to capillaries in the vascular bed and formed tubular structures. The vascularized hCMCs could survive after transplantation into the necks of rats via blood vessel anastomosis (169).

In vitro Perfusion
Techniques for maintaining adequate oxygen and nutrient availability during the manufacturing process include the
development of cartridges that reproduce the convective-diffusive properties of oxygen transportation present in native myocardial tissue (170). Another approach is culturing cells on a simulated capillary network with medium containing an oxygen carrier (perfluorocarbon) that mimics hemoglobin (171, 172). The hemoglobin mimic significantly increased the expression of cardiac markers and improved the contractile performance of constructs composed of primary neonatal CMs and fibroblasts. Small intestinal submucosa could be utilized to enhance perfusion with rat primary endothelial cells forming a network in pre-existing vessel structures (173). AngioChip technology (174) incorporates a perfusable, 3D microchannel network that recapitulates the native vascular interface and, because it is compatible with current practices in both laboratories and industry, can be adapted to produce a variety of tissue types. Perfusion can also be improved by culturing cardiac tissue constructs under dynamic conditions [e.g., on a rocking platform; (158)]. This approach was used during the manufacture of large (2 cm × 4 cm) patches for subsequent testing in a swine MI model and was associated with improvements in not only cell viability, but also in measures of hCMP maturation (23). Notably, some evidence suggests that the contractile properties of hCMPs can be enhanced by perfusing them in rhythmic pulses, rather than a continuous static flow (175).

**Engineered Vascular Networks**

Rather than relying solely on infiltration from the native circulatory system, thicker hCMPs will likely require at least some amount of engineered vascularity before transplantation. Vascularization can be induced during the manufacturing process by encapsulating a sacrificial gelatin mesh in scaffold material and then melting the gelatin mesh away, leaving behind a network of interconnected microfluidic channels. When seeded with human microvascular ECs, the sacrificial scaffolds produced a rudimentary endothelial network (176). An alternative strategy mimics the endogenous angiogenic process by using a sustained-release preparation of the angiogenic factor thymosin β to promote and guide the outgrowth of vessels from explanted arteries and veins to form a capillary bed within a hydrogel scaffold (177). Vessel growth can also be directed with micropatterned polyglycerol sebacate scaffolds. After transplantation, host blood cells infiltrated into the microvessels as the scaffold degraded (178). Micropatterning has also been used to organize ECs into “cords,” which guide the formation of capillaries that integrate with the host tissue after transplantation (179).

One of the novel reports of 3D printed vessels used a thermal inkjet printer to print mixtures of human microvascular ECs and fibrin, forming micro-sized fibrin channels lined with confluent cells (180). Vascular networks have also been bioprinted with an advanced extrusion system that produced a sheath of photoactive, cell-laden bioink around an alginate core. After UV crosslinking, the alginate was dissolved with a Ca²⁺-chelating agent, allowing the cells to proliferate, spread, and form a perfusable biomimetic vascular network (140). However, the penetration of UV radiation is limited. Polymerization can be induced at greater depths via enzymatic reactions, such as the thrombin-induced cleavage of fibrinogen.
into fibrin. This strategy has been combined with the co-printing of vascular and cellular inks in cast ECM material to generate markedly thick (>1 cm) engineered osteogenic tissues (181).

**Transplantation of hCMP Constructs**

**hCMP Delivery Methods**

Delivery methods for cells and tissues could be categorized into invasive and non-invasive approaches, both often featuring low engraftment rates (12). Transplantation of hCMPs mainly falls into invasive delivery, requiring open-chest surgery, and suturing/attaching the patch onto the epicardium (23, 62). This method typically offers an enhanced engraftment and survival rate compared with cell injection into the injured myocardium. The widespread application of intra-myocardial cell injections has demonstrated a poor cell retention rate with induced damages to both exogenous and host cells due to a dramatic increase in flow velocity and shear stress (182). Studies have shown that repeated cell injections increase the therapeutic effects (183). However, invasive delivery methods are not optimal for repeated applications due to requirements of dedicated facilities and highly trained staff to perform open-chest surgery. As a result, invasive delivery of cells and hCMPs has challenged clinical translation of these therapies (184).

Alternatively, non-invasive delivery methods, such as intravascular (or intravenous) delivery and injectable hydrogel approaches, have been tested. Intravascular delivery has shown recirculation and redistribution of injected cells to other organs besides the target site (6). These methods have demonstrated improved cardiac function potentially due to the paracrine signaling mechanism as previously discussed (185). This method has the advantages of being non-invasive and possibility of repeated administrations, qualifying them a good choice from a clinical viewpoint (184). Recently, a novel minimally invasive method demonstrated epicardial delivery of hydrogels through the pericardial space (186). A pericardial device (catheter) delivers the hydrogel components through separate (coaxial) lumens and combines them after exiting the device, forming a stable hydrogel construct between the pericardium and epicardium layers. This method could help minimize the risks of extensive myocardial injury, thrombotic occlusion, and arrhythmia. Injectable hydrogels have been also increasingly tested as a minimally (or non) invasive delivery approach for cardiac patch systems (187, 188). In a clinical study, acellular alginate-based hydrogels were injected in MI patients, demonstrating the preservation of the LV indices and ejection fraction (189). However, a more recent large clinical trial, investigating the effect of injectable alginate hydrogels in patients with advanced HF, reported about 9% death within 30 days post-injection, while the control group had no fatalities (190). Therefore, while significant progress has been made in developing injectable cardiac patch systems, more efforts are required for their further improvement for efficient clinical use. These include further enhancement in biomechanical and biochemical properties of the hydrogel constructs to mimic the native tissue, improving cell viability and biomolecules activity, controlled degradation and immune response, and enhancement in the *in vivo* tracking of the patch (187, 191, 192).

**Animal Models to Test hCMPs**

Preclinical studies have utilized different animal models, including mice, rats, guinea pigs, swine, and non-human primates (Table 1). Choice of a suitable animal model with high predictive validity for safety profile and therapeutic outcomes is crucial for the clinical translational purposes. Initial studies of therapeutic efficacy of transplanted human cells or cardiac tissues were performed in immunocompromised rodents, including athymic rats and severe combined immunodeficiency mice, due to genetic manipulations and easy handling. However, the disparity of anatomy and physiology between rodents and human dampens the reliability of therapeutic outcomes (197). Subsequent preclinical studies utilize large animal models, including non-human primates and swine, demonstrating remuscularization and therapeutic efficacy with safety concerns of ventricular arrhythmias (42, 196, 198). Large animal models are more reliable and relevant for preclinical studies compared with rodent models. However, the high cost associated with large animal studies would limit their applications (41).

**Mechanisms of Action of hCMPs**

The ultimate goal of cardiac patch transplantation is to replace the injured myocardium with exogenously functional cardiac muscle. Preclinical studies from mice (199, 200), rats (201), guinea pigs (52, 193), porcine (50), and non-human primates (41) have demonstrated some degree of myocardial remuscularization of the fibrotic scar tissue with transplanted cardiac tissues. The clinical translation of this approach has met some challenges, first of which is the requirement of large quantities of exogenous CMs (and/or other cardiac cells) used to replenish lost tissue. Robust protocols for CM differentiation and scalability of CM production, together with cryopreservation and retrieval procedures following current good manufacturing practice (cGMP), have enabled generation of well-characterized PSC-CMs as an off-the-shelf therapy (202). Furthermore, it remains a critical issue to ensure long-term graft retention for maximal therapeutic efficacy based on the hypothesis that contractile force is correlated to the electromechanically integrated CMs (202). Gene manipulation has been adopted to increase cell retention. Overexpression of CCND2 (cyclin D2), a cell cycle activator, increased cell cycle activity and proliferation rate in hiPSC-CMs, thus improving engraftment rate from average 10 to 25% with a significant remuscularization of injured myocardium in mice (203). CM retention could also be enhanced via co-administration of pro-survival factors, such as Matrigel, cyclosporine A, pinacidil, ZVAD-fmk, insulin-like growth factor-1 (IGF-1), CHIR99021, and fibroblast growth factor 1 (FGF1) (50, 82, 163).

The lack of electromechanical coupling between hCMPs and host tissue is another challenge on the way of clinical translation of patch-based therapies. Super-aligned carbon nanotubes were utilized during the fabrication of cardiac tissues to enhance electrophysiological homogeneity due to the
### Table 1: Summary of various hCMP studies conducted in animal models of heart injuries.

| Animal model                                      | Cell type and number                                                                 | Delivery method/Material                                                                 | Vascularization | Observations                                                                                                                                                                                                 | Follow up |
|---------------------------------------------------|--------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| NOD/SCID gamma mice with MI (101)                 | Five Spheroids composed of hiPSC-CMs (2 x 10^5/spheroid)                              | Engineered fibrin cardiac patch                                                           | N/A             | Improved LVEF and FS; enhanced engraftment                                                                                                                                                                  | 4 weeks   |
| NOD/SCID gamma mice with MI (163)                 | 1 x 10^5 hiPSC-CM                                                                    | Engineered fibrin cardiac patch containing nanoparticles releasing CHIR99021 and FGF1  | N/A             | Enhanced cardiac function; reduced infarct size; increased engraftment with enhanced cell cycle activity of hiPSC-CMs                                                                                       | 4 weeks   |
| Guinea pigs with cryoinjury (193)                 | 1 x 10^6 hiPSC-CMs                                                                  | IM                                                                                       | N/A             | Improved mechanical function; reduced incidence of arrhythmias                                                                                                                                              | 4 weeks   |
| Guinea pigs with MI (52)                          | 5 x 10^6 hiPSC-CM and 2 x 10^6 hiPSC-ECs                                             | Engineered fibrin cardiac patch                                                            | Inclusion of IPSC-ECs                                  | Improve left ventricular function by 31%; remuscularization; vascularization; electrical coupling with host myocardium                                                                                     | 28 days   |
| Rats with MI (35)                                 | 4 x 10^7 Fetal rat ventricular muscle                                                | Engineered gelatin cardiac patch                                                          | N/A             | No significant change in cardiac function; surviving grafts                                                                                                                                                 | 5 weeks   |
| Rats with MI (36)                                 | 3 x 10^5 Fetal rat CMs                                                               | Engineered alginate cardiac patch                                                          | N/A             | No significant change; Engraftment with intensive neovascularization; integration; attenuate LV dilatation                                                                                             | 9 weeks   |
| Normal athymic rats Sprague Dawley (56)           | ESC-CMs and iPSC-CMs; HUVEC; MSCs; MEFs                                              | Engineered collagen cardiac patch                                                          | Inclusion of stromal supporting cells                 | Form grafts containing microvessels; Enhanced formation of vessel-like structures                                                                                                                        | 1 week    |
| Rats with MI (88)                                 | 1 x 10^8 Bone marrow mesenchymal stem cells                                         | Engineered silk fibron/hyaluronic acid cardiac patch                                     | N/A             | Therapeutic efficacy; improved LV wall thickness; high viability; neovascularization                                                                                                                        | 8 weeks   |
| Nude athymic rats with MI (39, 194)               | 2.5 x 10^6 hESC-CMs                                                                  | Engineered collagen cardiac patch                                                          | N/A             | No significant changes of LVEF; Preserved heart function revealed by tagged magnetic resonance imaging; high engraftment                                                                               | 4 weeks   |
| Athymic rats with MI (40)                         | 2.2 x 10^6 iPSC-CMs; 3.4 x 10^6 human pericytes                                    | Engineered fibrin cardiac patch                                                            | Inclusion of human pericytes                          | Improved cardiac function; reduced infarct size; engraft onto host heart                                                                                                                                   | 4 weeks   |
| Rats with acute MI (139)                          | Acellular                                                                            | Decellularized porcine myocardial slice                                                    | Utilization of decellularized porcine myocardium mimicking native ECM | Improved cardiac function; attach to host myocardium; prevent LV wall thinning; vascularization                                                                                                          | 4 weeks   |
| Rats and porcine with MI (152)                    | Acellular; synthetic cardiacstromal cells                                           | Cardiac patch composed of a decellularized porcine myocardium                             | Enhanced cardiac recovery with reduced scar and promoted angiogenesis in rat model; therapeutic efficacy in porcine model                            | 3 weeks   |
| Porcine with MI (113)                             | 1.5 x 10^7 Skeletal myoblasts from mini-pigs                                       | Cell sheets covered with omentum flap                                                      | Utilization of omentum flap for revascularization     | Improved cardiac function; Reduced infarct size; increased angiogenesis                                                                                                                                     | 8 weeks   |
| Porcine minipigs with MI (114)                    | iPSC-CMs                                                                             | Cell sheets                                                                               | N/A             | Improved cardiac performance and attenuated left ventricular remodeling; poor engraftment                                                                                                                    | 8 weeks   |
| Normal porcine mini-pigs (115)                    | iPSC-CMs                                                                             | Cell sheets with an omentum flap                                                          | Inclusion of an omentum flap                          | Enhanced survival and engraftment; rich vasculature                                                                                                                                                    | 8 weeks   |
| Immunosuppressed Yorkshire pigs with MI (51)      | 4 x 10^5 hiPSC-VC (ECs and SMCs)                                                     | Engineered fibrin cardiac patch                                                            | Inclusion of iPSC-VCs (ECs and SMCs)                  | Increased BZ contractile function and ATP turnover rate with attenuated regional wall stress, neovascularization and improved BZ perfusion                                                             | 4 weeks   |

(Continued)
| Animal model | Cell type and number | Delivery method/Material | Vascularization | Observations | Follow up |
|--------------|----------------------|--------------------------|-----------------|--------------|-----------|
| Porcine with acute MI (50) | 6 × 10^6 total iPSC-cardiovascular cells (CMs, ECs, and SMCs; each 2 × 10^6) | IM + fibrin patch containing IGF | Inclusion of IPSC-ECs, SMCs | Improved left ventricular function; reduced infarct size; Integration with host myocardium; vascularization; | 4 weeks |
| Porcine with ICM (116) | 5 × 10^6 iPSC-CMs | Cell sheets with omental flap | Utilization of omentum flap | Enhanced therapeutic effects and survival; | 3 months |
| Porcine with MI (23) | iPSC-Cardiac cells (4 × 10^6 CMs, 2 × 10^6 ECs, and 2 × 10^6 SMCs) | Engineered fibrin cardiac patch | Inclusion of IPSC-ECs, -SMCs | Improved left ventricular function; reduced infarct size; reduced LV wall stress; no significant changes in arrhythmogenicity | 4 weeks |
| Porcine with MI (195) | Acellular; exosomes derived from iPSC-Cardiac cells (iPSC-CMs, -ECs, -SMCs) | IM | N/A | Improve myocardial recovery without increasing the frequency of arrhythmogenic | 4 weeks |
| Non-human primate Macaca nemestrina with MI (41) | 1 × 10^9 (1 billion) hESC-CMs | IM | N/A | Remuscularization; vascularization; electromechanical coupling; arrhythmias | 3 months |
| Non-human primate Macaca fascicularis with MI (196) | 1 × 10^9 iPSC-CMs | IM | N/A | Improved cardiac function; Survive for 12 weeks; electrical coupling; ventricular tachycardia (transient) | 12 weeks |
| Non-human primate macaque monkeys with MI (42) | ~750 million hESC-CMs | IM | N/A | Improved cardiac function; formation of electromechanical junctions; ventricular arrhythmias | 3 months |
| One patient with severe heart failure (93) | 4 × 10^6 hESC-derived Isl-1+ SSEA-1+ cells | Engineered fibrin cardiac patch | N/A | Symptomatically improved LVEF; new-onset contractility; no complications | 3 months |
| Seven patients with ischemic cardiomyopathy (UMIN000008013) (118) | 3 × 10^6 autologous skeletal muscle | Cell sheet | N/A | Improved LVEF; improved patient status | 26 weeks |
| Six patients with severe ischemic left ventricular dysfunction (NCT02057900) (91) | 8.2 × 10^6 hESC-derived cardiovascular progenitors | Engineered fibrin cardiac patch | N/A | Uneventful recoveries; no safety concerns, such as tumor, arrhythmias, alloimmunization | 1 year |
| Four patients with dilated cardiomyopathy (UMIN000000660) (119) | 4.5–7.5 × 10^6 autologous skeletal muscle | Cell sheet | N/A | Improved LVEF in two patients; reduced cardiac hypertrophy | 3 months |

FOGF1, fibroblast growth factor 1; LVEF, left ventricular ejection fraction; FS, fractional shortening; IM, intra-myocardial delivery; HUVECs, human umbilical vein endothelial cells; MSCs, human marrow stromal cells; MEFs, mouse embryonic fibroblasts; IGF, insulin growth factor; ICM, ischemic cardiomyopathy.
anisotropic conductivity of their aligned structure (204). In another study, electrospun nanofibrous scaffolds with enhanced conductivity were demonstrated to promote electrical coupling of the patch, showing potential for fabrication of clinically relevant hCMP products (205). One major aspect that must be carefully studied, when working on electromechanical integration of exogenous CMs with host myocardium is the likely potential to trigger arrhythmias, as discussed in the previous sections (41).

Low CM survival rates, as little as 10%, have been usually associated with functional benefits from hCMP transplantsations (39, 51, 194). Patch constructs composed of non-CMs have also shown improved cardiac function (51). These data collectively suggest an alternative mechanism of action, based on paracrine signaling, where cell secreted signals, including extracellular vesicles, mediate cardiac repair via increasing CM survival and neovascularization and decreasing apoptosis and inflammation (206). Paracrine signaling was further evidenced by a study where exosomes secreted from combination of iPSC-derived CMs, ECs, and SMCs yielded cardioprotective effects similar to that obtained from direct cells injection in a porcine model of MI (195). Further, acellular hCMPs composed of non-viable/irradiated cells (39) or decellularized porcine myocardial tissues (139) have shown therapeutic benefits after transplantation, through the proposed mechanism of mechanical stabilization. Thus, the therapeutic benefits associated with hCMP transplantation could be a combination of any or all of mechanisms including remuscularization, paracrine signaling, and mechanical stabilization (202, 207).

Safety Concerns
Occurrence of arrhythmias is a critical safety concern for clinical applicability of cardiac patch therapies. Sine large animal models more closely approximate the human heart's physiology, function, and anatomy, they have been increasingly used to assess arrhythmias in cardiac patch studies (41). Preclinical studies of non-human primates demonstrated transient non-fatal arrhythmias during 2 weeks after transplantation, followed by a subsequent decrease in those irregularities (41, 196). Ventricular arrhythmias occurred in porcine models have been more frequent and lethal than those in non-human primate models (2 out of every 7 pigs) (198). It is currently viewed that disorder of impulse generation at the interface between engrafted CMs and host myocardium could induce ventricular arrhythmias (42, 198). Further investigation of arrhythmic complications will be necessary before translation into patients.

Autologous cell transplantation offers an advantageous option based on the hypothesis that autologous cell transplantation could induce no immunological response due to the acceptable human leukocyte antigens (HLA) match. However, accumulating evidence prove that the clinical translation of autologous cells could become complicated by limitations, such as variability from batch to batch, requiring a detailed characterization and quality control of each batch. The initial hypothesis that transplantation of autologous iPSC derivatives would induce no immunogenicity has been challenged by some recent studies (70, 71).

For a long time in clinical practice, inhibition of the immunological responses has been mainly through the use of immunosuppressive drugs, such as cyclosporine, dexamethasone, and FK-506. With side effects induced by such immunosuppressants, there is a trade-off between efficacy and toxicity. High-dose immunosuppression would result in toxicity and associated complications, while low-dose immunosuppression would lead to allograft rejection. The choice of transient or chronic exposure of immunosuppressants would be based on the presumed mechanism of action, as discussed previously (184, 208). In addition, immunological tolerance could be induced via host conditioning by activation/adoptive transfer of regulatory T cells (209). Short-term administration of nanobiologics targeting macrophages could benefit long-term allograft survival (210). Other strategies have been adopted to reduce immunogenicity. Modern genome-editing tools [e.g., zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), or the clustered regulatory interspaced short palindromic repeat (CRISPR)/Cas-9 system; (37, 211, 212)] have enabled the development of minimally immunogenic iPSC lines by knocking out key components of major histocompatibility complexes (MHCs) I and II [Beta2 microglobulin (B2M) and MHC II transactivator (CIITA)] (213). This is done by combining MHC gene inactivation with the overexpression of CD47, a ubiquitous membrane protein that directly regulates T-cell immunity (214), and by disrupting the genes for HLA (215). These genetically modified hiPSCs could be used to generate a stockpile of “off-the-shelf” cardiac cells and hCMPS for administration to patients in emergency situations without the need for concomitant immunosuppressive therapies.

Summary—Current Challenges and Future Perspectives
The potential benefits of hCMPS for the treatment of myocardial injury and disease are readily observable in preclinical studies, and at least one small study in patients is currently underway (120). Conventional methods for manufacturing hCMPS include suspending cells in scaffolds of biocompatible material or growing 2D sheets in culture and stacking them to form multilayered constructs. More advanced technologies, such as micropatterning and CAD-guided 3D printing with bioinks have given researchers the tools to control the architecture of hCMPS at resolutions that match the scale of interactions between individual cells or between cells and the ECM. Most studies, however, have been conducted with hCMPS at relatively small scales that are not suitable for administration to patients. The size and (especially) thickness of hCMPS are often restricted by the diffusion limitations of oxygen, nutrients, and other biologically active molecules, which requires CMs to be within 100–200 µm distance from the capillaries. Thus, the clinical translation of hCMP technology will require the development of protocols for manufacturing larger and thicker constructs that are adequately vascularized and fully couple
with the circulatory and electromechanical systems of the native myocardium.

**AUTHOR CONTRIBUTIONS**

LW, VS, and JZ contributed to the overall design of the manuscript, collecting the data, and writing the article. JZ supervised the entire manuscript preparation process, figures design and creation, obtaining the necessary permits, etc. All authors contributed to the article and approved the submitted version.

**REFERENCES**

1. Laslett LJ, Alagona P Jr., Clark BA III, Drozda JP, Saldivar F, Wilson SR, et al. The worldwide environment of cardiovascular disease: prevalence, diagnosis, therapy, and policy issues: a report from the American College of Cardiology. *J Am Coll Cardiol*. (2012) 60(Suppl. 25):S1–49. doi: 10.1016/j.jacc.2012.11.002

2. Tratuzalos E, Abilez OJ, Shukla P, Wu JC. Engineered heart tissues and induced pluripotent stem cells: macro- and microstructures for disease modeling, drug screening, and translational studies. *Adv Drug Deliv Rev*. (2016) 96:234–44. doi: 10.1016/j.addr.2015.09.010

3. Evans MA, Sano S, Walsh K. Cardiovascular disease, aging, and clonal hematopoiesis. *Annu Rev Pathol*. (2020) 15:419–38. doi: 10.1146/annurev-pathmed-021419-032544

4. Bergmann O, Zduneck S, Felker A, Salehpour M, Alkass K, Bernard S, et al. Dynamics of cell generation and turnover in the human heart. *Cell*. (2015) 161:1566–75. doi: 10.1016/j.cell.2015.05.026

5. Travers JG, Kamal FA, Robbins J, Yutzey KE, Blaxall BC. Cardiac fibrosis: the fibroblast awakens. *Circ Res*. (2016) 118:1021–40. doi: 10.1161/CIRCRESAHA.115.306565

6. Zhang J, Zhu W, Radisic M, Vunjak-Novakovic G. Can we engineer a human cardiac patch for therapy? *Circ Res*. (2018) 123:244–65. doi: 10.1161/CIRCRESAHA.118.311213

7. Parsa H, Ronaldson K, Vunjak-Novakovic G. Bioengineering methods for myocardial regeneration. *Adv Drug Deliv Rev*. (2016) 96:195–202. doi: 10.1016/j.addr.2015.06.012

8. Fujita B, Zimmermann WH. Myocardial tissue engineering for regenerative applications. *Curr Cardiol Rep*. (2017) 19:78. doi: 10.1007/s11886-017-0892-4

9. Pomeroy JE, Helfer A, Bursac N. Biomaterializing the promise of cardiac tissue engineering. *Biotechnol Adv*. (2020) 42:107353. doi: 10.1016/j.biotechadv.2019.02.009

10. Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson SM, Li B, et al. Bone marrow cells regenerate infarcted myocardium. *Nature*. (2001) 410:701–5. doi: 10.1038/35070587

11. Nygren JM, Jovinge S, Breitbach M, Säwén P, Röll W, Hescheler J, et al. Bone marrow-derived hematopoietic cells generate cardiomyocytes at a low frequency through cell fusion, but not transdifferentiation. *Nat Med*. (2004) 10:494–501. doi: 10.1038/nm1040

12. Nguyen PK, Rhee JW, Wu JC. Adult stem cell therapy and heart failure, 2000 to 2016: a systematic review. *JAMA Cardiol*. (2016) 1:831–41. doi: 10.1001/jamacardio.2016.2225

13. Ogle BM, Bursac N, Domian I, Huang NE, Menasché P, Murry CE, et al. Distilling complexity to advance cardiac tissue engineering. *Sci Transl Med*. (2016) 8:342ps13. doi: 10.1126/scitranslmed.aad2304

14. Goldfracht I, Efriam Y, Shinnawi R, Kovalov E, Huber I, Gepstein A, et al. Engineered heart tissue models from hiPSC-derived cardiomyocytes and cardiac ECM for disease modeling and drug testing applications. *Acta Biomater*. (2019) 124:95–159. doi: 10.1016/j.actbio.2019.05.016

15. Meyer T, Tiburcy M, Zimmermann WH. Cardiac macrotissues-on-a-plate models for phenotypic drug screens. *Adv Drug Deliv Rev*. (2019) 140:93–100. doi: 10.1016/j.addr.2019.03.002

16. Turnbull IC, Mayourian J, Murphy JF, Stillitano F, Ceholski DK, Costa KD. Cardiac tissue engineering models of inherited and acquired cardiomyopathies. *Methods Mol Biol*. (2018) 1816:145–59. doi: 10.1007/978-1-4939-8597-5_11

17. Zhao Y, Rafatian N, Feric NT, Cox BJ, Aschar-Sobbi R, Wang EY, et al. A platform for generation of chamber-specific cardiac tissues and disease modeling. *Cell*. (2019) 176:913–27.e18. doi: 10.1016/j.cell.2018.11.042

18. Giacomelli E, Meraviglia V, Campostrini G, Cochrane A, Cao X, van Helden RWJ, et al. Human-iPSC-Derived cardiac stem cells enhance maturation in 3D cardiac microtissues and reveal non-cardiomyocyte contributions to heart disease. *Cell Stem Cell*. (2020) 26:862–79.e11. doi: 10.1016/j.stem.2020.05.004

19. Shadrin YI, Allen BW, Qian Y, Jackman CP, Carlson AL, Juhas ME, et al. Cardiopath platform enables maturation and scale-up of human pluripotent stem cell-derived engineered heart tissues. *Nat Commun*. (2017) 8:1825. doi: 10.1038/s41467-017-01946-x

20. Weinberger F, Mannhardt I, Eschenhagen T. Engineering cardiac tissue: a maturing field of research. *Circ Res*. (2017) 120:1487–500. doi: 10.1161/CIRCRESAHA.117.310738

21. Eschenhagen T, Fink C, Remmers U, Scholz H, Wattchow I, Well J, et al. Three-dimensional reconstitution of embryonic cardiomyocytes in a collagen matrix: a new heart muscle model system. *Faseb J*. (1997) 11:683–94. doi: 10.1096/fasebj.11.8.940969

22. Lian X, Hisao C, Wilson G, Zhu K, Hazeltine LB, Azarin SM, et al. Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling. *Proc Natl Acad Sci USA*. (2012) 109:E1848–57. doi: 10.1073/pnas.1200250109

23. Shimizu I, Minamino T. Physiological and pathological cardiac hypertrophy. *J Mol Cell Cardiol*. (2016) 97:245–62. doi: 10.1016/j.yjmcc.2016.06.001

24. Gao L, Gregorich ZR, Zhu W, Mattappally S, Oduk Y, Lou X, et al. Large cardiac muscle patches engineered from human induced-pluripotent stem cell-derived cardiac tissues improve recovery from myocardial infarction in swine. *Circulation*. (2018) 137:1712–30. doi: 10.1161/CIRCULATIONAHA.117.030785

25. Shimizu T, Yamato M, Kikuchi A, Okano T. Cell sheet engineering for myocardial tissue reconstruction. *Biomaterials*. (2003) 24:2309–16. doi: 10.1016/S0142-6186(03)00110-8

26. Bursac N, Loo Y, Leong K, Tung L. Novel anisotropic engineered cardiac tissues: studies of electrical propagation. *Biochem Biophys Res Commun*. (2007) 361:847–53. doi: 10.1016/j.bbrc.2007.07.138

27. Banerjee I, Fuseler JW, Price RL, Bong TK, Baudino TA. Determination of cell types and numbers during cardiac development in the neonatal and adult rat and mouse. *Am J Physiol Heart Circ Physiol*. (2007) 293:H1883–91. doi: 10.1152/ajpheart.00514.2007

28. Bursac N, Loo Y, Leong K, Tung L. Novel anisotropic engineered cardiac tissues: studies of electrical propagation. *Biochem Biophys Res Commun*. (2007) 361:847–53. doi: 10.1016/j.bbrc.2007.07.138

29. Banerjee I, Fuseler JW, Price RL, Bong TK, Baudino TA. Determination of cell types and numbers during cardiac development in the neonatal and adult rat and mouse. *Am J Physiol Heart Circ Physiol*. (2007) 293:H1883–91. doi: 10.1152/ajpheart.00514.2007

30. Fleischer S, Vunjak-Novakovic G. Cardiac tissue engineering: from repairing to modeling the human heart. In: Reis RL, editor. *Encyclopedia of Tissue Engineering and Regenerative Medicine*. Oxford: Academic Press (2019). p. 131–44. doi: 10.1016/B978-0-12-801238-3.65543-5

31. Wobma H, Vunjak-Novakovic G. Tissue engineering and regenerative medicine 2015: a year in review. *Tissue Eng Part B Rev*. (2016) 22:101–13. doi: 10.1089/ten.teb.2015.0535
32. Soompan MH, Koh GY, Klug MG, Field LJ. Formation of nascent intercalated disks between grafted fetal cardiomyocytes and host myocardium. Science. (1994) 264:98–101. doi: 10.1126/science.8140423
33. Souren JE, Schneidemeng C, Verkleij AJ, Van Wijk R. Factors controlling the rhythmic contraction of collagen gels by neonatal heart cells. In Vitro Cell Dev Biol Anim. (2008) 44:199–204. doi: 10.1007/s11626-008-9430-z
34. Souren JE, Peters RC, Van Wijk R. Collagen gels populated with rat neonatal heart cells can be used for optical recording of rhythmic contractions which also show ECG-like potentials. EXPERIENTIA. (1994) 50:712–6. doi: 10.1007/BF01919368
35. Li RK, Jia ZQ, Weisel RD, Mickle DA, Choi A, Yau TM. Survival and function of bioengineered cardiac grafts. Circulation. (1999) 100(Suppl. 19):I63–9. doi: 10.1161/01.CIR.100.19.163
36. Leor J, Aboulafia-Etzion S, Dar A, Shapiro L, Barbash IM, Battler J, et al. Human embryonic stem cell-derived cardiomyocytes can regenerate non-human primate hearts. Nature. (2014) 510:273–7. doi: 10.1038/nature13233
37. Zhang S, Dutton JR, Su L, Zhang J, Ye L. The influence of a spatiotemporal 3D environment on endothelial cell differentiation of human induced pluripotent stem cells. Biomaterials. (2014) 35:3786–93. doi: 10.1016/j.biomaterials.2014.01.037
38. Caspi O, Lesman A, Basevitch Y, Gepstein A, Arbel G, Habib IH, et al. Tissue-engineered cardiac patch for advanced functional maturation of human ESC-derived cardiomyocytes. Circulation. (2013) 127:997–1008. doi: 10.1161/CIRCULATIONAHA.112.006041
39. Weinberger F, Breckwoldt K, Pecha S, Kelly A, Geeritz B, Starbatty J, et al. Cardiac repair in guinea pigs with human engineered heart tissue from induced pluripotent stem cells. Sci Transl Med. (2016) 8:363ra148. doi: 10.1126/scitranslmed.aaf781
40. Choy KD, Yu J, Smuga-Otto K, Salvagiotto G, Rehuraw V, Vodyanik M, et al. Hematopoietic and endothelial differentiation of human induced pluripotent stem cells. Stem Cells. (2009) 27:559–67. doi: 10.1002/stem.20080922
41. Shu B, Xie JL, Xu YB, Yu JX, Shi Y, Liu J, et al. Directed differentiation of skin-derived precursors into fibroblast-like cells. Int J Clin Exp Pathol. (2014) 7:1478–86.
42. Gao L, Yang L, Wang L, Geng Z, Wei Y, Gourley G, et al. Relationship between the efficacy of cardiac cell therapy and the inhibition of differentiation of human iPSC-derived nonmyocyte cardiac cells into myofibroblast-like cells. Circ Res. (2018) 123:1313–25. doi: 10.1161/CIRCRESAHA.118.313094
43. Tulloch NL, Mushkel V, Razumova MV, Korte FS, Regnier M, Hauch KD, et al. Growth of engineered human myocardium with mechanical loading and vascular coculture. Circ Res. (2011) 109:47–59. doi: 10.1161/CIRCRESAHA.110.237206
44. Zhang S, Dutton JR, Su L, Zhang J, Ye L. The influence of a spatiotemporal 3D environment on endothelial cell differentiation of human induced pluripotent stem cells. Biomaterials. (2014) 35:3786–93. doi: 10.1016/j.biomaterials.2014.01.037
45. Patsch C, Challet-Meylan L, Thoma EC, Uriech E, Hecket T, O’Sullivan JE, et al. Generation of vascular endothelial and smooth muscle cells from human pluripotent stem cells. Nat Cell Biol. (2015) 17:994–1003. doi: 10.1038/ncb3205
46. Zhang J, Chu LF, Hou Z, Schwartz MP, Hacker T, Vickerman V, et al. Functional characterization of human pluripotent stem cell-derived arterial endothelial cells. Proc Natl Acad Sci USA. (2017) 114:E6072–8. doi: 10.1073/pnas.1702295114
47. Zhang J, Tao R, CampbellKF, Carvalho JF, Ruiz EC, Kim GC, et al. Functional cardiac fibroblasts derived from human pluripotent stem cells via second heart field progenitors. Nat Commun. (2019) 10:2238. doi: 10.1038/s41467-019-09831-5
48. Giacomelli E, Bellin M, Orlova VV, Mummery CL. Co-differentiation of human pluripotent stem cells-derived cardiomyocytes and endothelial cells from cardiac mesoderm provides a three-dimensional model of cardiac microtissue. Curr Protoc Hum Genet. (2017) 59:21.9.1–21.9.22.
49. Gao L, Kupfer ME, Jung JP, Yang L, Zhang P, Da Sie Y, et al. Myocardial tissue engineering with cells derived from human-induced pluripotent stem cells and a native-like, high-resolution, 3-dimensionally printed scaffold. Circ Res. (2017) 120:1318–25. doi: 10.1161/CIRCRESS.116.310277
50. Lian B, Jackman CP, Li Y, Bursac N. Developmental stage-dependent effects of cardiac fibroblasts on function of stem cell-derived engineered cardiac tissues. Sci Rep. (2017) 7:42290. doi: 10.1038/srep42290
51. Ronaldson-Bouchard K, Ma SP, Yeager K, Chen T, Song L, Sirabella D, et al. Advanced maturation of human cardiac tissue grown from pluripotent stem cells. Nature. (2018) 556:239–43. doi: 10.1038/s41586-018-0161-3
52. Evans MJ, Kaufman MH. Establishment in culture of pluripotential cells from mouse embryos. Nature. (1981) 292:154–6. doi: 10.1038/292154a0
53. Kim K, Leriou P, Yabuuchi A, Lengerke C, Ng K, West J, et al. Histocompatible embryonic stem cells by parthenogenesis. Science. (2007) 315:482–6. doi: 10.1126/science.1133542
54. Sayed N, Liu C, Wu JC. Translation of human-induced pluripotent stem cells: from clinical trial in a dish to precision medicine. J Am Coll Cardiol. (2016) 67:2161–76. doi: 10.1016/j.jacc.2016.01.083
55. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frané JL, Tian S, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. (2007) 318:1917–20. doi: 10.1126/science.1151526
56. Huangfu D, Osafune K, Maeh R, Guo W, Eijkelkoom Bo A, Chen S, et al. Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nat Biotechnol. (2008) 26:1269–75. doi: 10.1038/nbt.1502

Itskovitz-Eldor J, Schuldiner M, Karsenti D, Eden A, Yanuka O, Amit M, et al. Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes. J Clin Invest. (2001) 108:407–14. doi: 10.1172/JCI121331

He QJ, Ma Y, Lee Y, Thomson JA, Kamp TJ. Human embryonic stem cells develop into multiple types of cardiac myocytes: action potential characterization. Circ Res. (2003) 93:32–9. doi: 10.1161/01.RES.0000080317.92718.99

Osafune K, Karon L, Borowik M, Martinez RJ, Fitz-Gerald CS, Sato Y, et al. Marked differences in differentiation propensity among human embryonic stem cell lines. Nat Biotechnol. (2008) 26:313–5. doi: 10.1038/nbt1383

Mummery CL, Zhang J, Ng ES, Elliott DA, Elefanty AG, Kamp TJ. Differentiation of human embryonic stem cells and induced pluripotent stem cells to cardiomyocytes: a methods overview. Circ Res. (2012) 111:344–58. doi: 10.1161/CIRCRESAHA.110.227512

Halloin C, Schwanke K, Löbel W, Franke A, Szepes M, Biswanath S, et al. Continuous WNT control enables advanced hiPSC cardiac processing and prognostic surface marker identification in chemically defined suspension culture. Stem Cell Rep. (2019) 13:366–79. doi: 10.1016/j.stemcr.2019.06.004

Devalia HD, Schwach V, Ford JW, Milnes JT, El-Haou S, Jackson C, et al. Atrial-like cardiomyocytes from human pluripotent stem cells are a robust preclinical model for assessing atrial-selective pharmacology. EMBO Mol Med. (2015) 7:394–410. doi: 10.15252/emmm.201404757

Lee JH, Protze SL, Laksman Z, Backx PH, Keller GM. Human embryonic stem cell-derived atrial and ventricular cardiomyocytes develop from distinct mesoderm populations. Cell Stem Cell. (2017) 21:179–94.e4. doi: 10.1016/j.stem.2017.07.003

Laflamme MA, Chen KY, Naumova AV, Muskheli V, Fugate JA, Dupras SK, et al. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat Biotechnol. (2007) 25:1015–24. doi: 10.1038/nbt1323

Kattman SL, Witty AD, Gagliardi M, Dubois NC, Niapour M, Hotta A, et al. Stage-specific optimization of activin/nodal and BMP signaling promotes cardiomyocyte differentiation of mouse and human pluripotent stem cell lines. Cell Stem Cell. (2011) 8:228–40. doi: 10.1016/j.stem.2010.12.008

Lian X, Zhang J, Azarin SM, Zhu K, Hazeltine LB, Bao X, et al. Directed cardiomyocyte differentiation from human pluripotent stem cells by modulating Wnt/b-catenin signaling under fully defined conditions. Nat Protoc. (2013) 8:162–75. doi: 10.1038/nprot.2012.150

Kropp C, Kempf H, Halloin C, Robles-Diaz D, Franke A, Scheper T, et al. Impact of feeding strategies on the scalable expansion of human pluripotent stem cells in single-use stirred tank bioreactors. Stem Cells Transl Med. (2016) 5:1289–301. doi: 10.5966/sctm.2015-0253

Ackermann M, Kempf H, Hetzel M, Hesse C, Hashchhina AR, Brinkert K, et al. Biorreector-based mass production of human iPSC-derived macrophages enables immunotherapies against bacterial airway infections. Nat Commun. (2019) 8:5088. doi: 10.1038/s41467-018-07570-7

Chen VC, Ye J, Shukla P, Hua G, Chen D, Lin Z, et al. Development of a scalable suspension culture for cardiac differentiation from human pluripotent stem cells. Stem Cell Rep. (2015) 15:365–75. doi: 10.1016/j.stemcr.2015.08.003

Chi NH, Yang MC, Chung TW, Chen JY, Chou NK, Wang SS. Cardiac repair achieved by bone marrow mesenchymal stem cells/silk fibroin/hyaluronic acid patches in a rat of myocardial infarction model. Biomaterials. (2012) 33:5541–51. doi: 10.1016/j.biomaterials.2012.04.030

Menasché P, Vanneaux V, Fabreguettes JR, Bel A, Tosca L, Garcia S, et al. Towards a clinical use of human embryonic stem cell-derived cardiac progenitors: a translational experience. Eur Heart J. (2015) 36:743–50. doi: 10.1093/eurheartj/het192

Menasché P, Vanneaux V, Hagège A, Bel A, Cholley B, Caccippuito L, et al. Human embryonic stem cell-derived cardiac progenitors for severe heart failure treatment: first clinical case report. Eur Heart J. (2015) 36:2011–7. doi: 10.1093/eurheartj/ehv189

Menasché P, Vanneaux V, Hagège A, Bel A, Cholley B, Parouchev A, et al. Transplantation of human embryonic stem cell-derived cardiovascular progenitors for severe ischemic left ventricular dysfunction. J Am Coll Cardiol. (2018) 71:429–38. doi: 10.1016/j.jacc.2017.11.047

Qasim M, Haq F, Kang MH, Kim JH. 3D printing approaches for cardiac tissue engineering and role of immune modulation in tissue regeneration. Int J Nanomedicine. (2019) 14:1311–33. doi: 10.2147/IJIN.S189587

Tomov ML, Theus A, Sarasan R, Chen H, Serpooshan V. 3D bioprinting of cardiovascular tissue constructs: cardiac bioksins. In: Serpooshan V, Wu SM, editors. Cardiovascular Regenerative Medicine: Tissue Engineering Clinical Applications. Cham: Springer International Publishing (2019). p. 63–77. doi: 10.1007/978-3-030-20047-3_4

Tomov ML, Gil CJ, Cetnar A, Theus AS, Lima BJ, Nish JE, et al. Engineering functional cardiac tissues for regenerative medicine applications. Curr Cardiol Rep. (2019) 21:105. doi: 10.1186/s11868-019-1178-9

Nguyen DC, Hookway TA, Wu Q, Iha R, Freiminger MK, Chen X, et al. Microscale generation of cardiospheres promotes robust enrichment of cardiomyocytes derived from human pluripotent stem cells. Stem Cell Rep. (2014) 3:260–8. doi: 10.1016/j.stemcr.2014.06.002

Polonchuk L, Chabria M, Badi L, Hofflack JC, Figtree G, Davies MJ, et al. Cardiac spheroids as promising in vitro models to study the human heart microenvironment. Sci Rep. (2017) 7:7005. doi: 10.1038/s41598-017-06385-8

Campbell M, Chabria M, Figtree GA, Polonchuk L, Gentile C. Stem cell-derived cardiac spheroids as 3D in vitro models of the human heart microenvironment. Methods Mol Biol. (2019) 2002:51–9. doi: 10.1007/7651_2018_187

Oltolina F, Zamperoni A, Colangelo D, Gregorletto L, Reano S, Pietronave S, et al. Human cardiac progenitor spheroids exhibit enhanced engraftment potential. PLoS ONE. (2015) 10:e0137999. doi: 10.1371/journal.pone.0137999

Zhao S, Xu Z, Wang H, Reese BE, Guschchina LV, Jiang M, et al. Bioengineering of injectable encapsulated aggregates of pluripotent stem cells for therapy of myocardial infarction. Nat Commun. (2016) 7:13306. doi: 10.1038/ncomms13306

Bartolos O, Zhuang ZW, Huang Y, Mikush N, Suh C, Bregai A, et al. ISL1 cardiac progenitor cells for cardiac repair after myocardial infarction. JCI Insight. (2016) 1:e08920. doi: 10.1172/jci.insight.8920

Mappappally S, Zhu W, Fast VG, Gao L, Worley C, Kannappan R, et al. Spheroids of cardiomyocytes derived from human-induced pluripotent stem cells improve recovery from myocardial injury in mice. Am J Physiol Heart Circ Physiol. (2018) 315:H327–39. doi: 10.1152/ajpheart.00688.2017

LaBarge W, Mappappally S, Kannappan R, Fast VG, Pretorius D, Berry JL, et al. Maturation of three-dimensional, hiPSC-derived cardiomyocyte spheroids utilizing cyclic, uniaxial stretch and electrical stimulation. PLoS ONE. (2019) 14:e0219442. doi: 10.1371/journal.pone.0219442

Ong CS, Fukunishi T, Nasha A, Blazeski A, et al. ISL1 cardiovascular progenitor cells for cardiac repair after myocardial infarction. ISCI Insight. (2016) 1:e08920. doi: 10.1172/jci.insight.8920

Ong CS, Fukunishi T, Zhang H, Huang CY, Nasha A, Blazeski A, et al. Biomaterial-free three-dimensional bioprinting of cardiac tissue using human induced pluripotent stem cell derived cardiomyocytes. Sci Rep. (2017) 7:4566. doi: 10.1038/s41598-017-05018-4

Zhu Y, Serpooshan V, Wu S, Demirci U, Chen P, Guven S. Tissue engineering of 3D organotypic microtissues by acoustic assembly. Biomaterials. (2017) 1576:301–12. doi: 10.1016/j.biomaterials.2017.05.039
107. Serpooshan V, Chen P, Wu H, Lee S, Sharma A, Hu DA, et al. Bioacoustic-enabled patterning of human iPSC-derived cardiacomyocytes into 3D cardiac tissue. *Biomaterials.* (2017) 131:47–57. doi: 10.1016/j.biomaterials.2017.03.037

108. Haraguchi Y, Shimizu T, Yamato M, Okano T. Regenerative therapies using cell sheet-based tissue engineering for cardiac disease. *Cardiol Res Pract.* (2011) 2011:845170. doi: 10.4061/2011/845170

109. Okano T, Yamada N, Sakai H, Sakurai Y. A novel recovery system for cultured cells using plasma-treated polyethylene dishes grafted with poly(N-isopropylacrylamide). *J Biomed Mater Res.* (1993) 27:1243–51. doi: 10.1002/jbm.b.820271005

110. Shimizu T, Yamato M, Isoy S, Akutsu T, Setomaru T, Abe K, et al. Fabrication of pulsatile cardiac tissue grafts using a novel 3-dimensional cell sheet manipulation technique and temperature-responsive cell culture surfaces. *Circ. Res.* (2002) 90:e40. doi: 10.1161/01.res.00000641032

111. Leor J, Landa N, Cohen S. Renovation of the injured heart with myocardial tissue engineering. *Expert Rev Cardiovasc Ther.* (2006) 4:239–52. doi: 10.1586/14797972.4.3.239

112. Reis LA, Chiu LL, Feric N, Fu L, Radisic M. Biomaterials in myocardial tissue engineering. *J Tissue Eng Regen Med.* (2010) 4:1145–20. doi: 10.1002/biom.201000009

113. Sato Y, Yoshikawa Y, Toda K, Fukushima S, Yamazaki K, Ono M, et al. Enhanced survival of transplanted human induced pluripotent stem-derived cardiac cells in a porcine ischemic cardiomyopathy model. *Circulation.* (2012) 126(11 Suppl. 1):S29–37. doi: 10.1161/CIRCULATIONAHA.111.84343

114. Sato Y, Yoshikawa Y, Toda K, Fukushima S, Yamazaki K, Ono M, et al. Safety and efficacy of autologous skeletal myoblast sheets (TCD-51073) for the treatment of severe chronic heart failure due to ischemic heart disease. *Circ. J.* (2015) 79:991–9. doi: 10.1253/circj.CJ-15-0243

115. Romero RM, Svardal MO, Rodean M, et al. Enhanced survival of transplanted human induced pluripotent stem cell-derived cardiomyocytes by the combination of cell sheets with the pedicled omental flap technique in a porcine model. *Circulation.* (2013) 128(11 Suppl. 1):88–94. doi: 10.1161/CIRCULATIONAHA.112.000366

116. Sato Y, Yoshikawa Y, Toda K, Fukushima S, Yamazaki K, Ono M, et al. Enhanced therapeutic effects of human iPSC derived-cardiac cells by combining cell sheets with omental flap technique in porcine ischemic cardiomyopathy model. *Sci Rep.* (2017) 7:8824. doi: 10.1038/s41598-017-08869-2

117. Matsui H, Okano T, Yamada N, Sakai H, Aoki Y, et al. Enhanced survival of transplanted human induced pluripotent stem cell-derived cardiomyocytes reassembled with defined cardiovascular populations ameliorate reduction in infarct heart function through cardiomyocyte-mediated neo-vasularization. *Stem Cells.* (2012) 30:1196–205. doi: 10.1002/stem.1089

118. Sato Y, Yoshikawa Y, Toda K, Fukushima S, Yamazaki K, Ono M, et al. Myocardial regeneration therapy using a scaffold-free skeletal-muscle-derived cell sheet in patients with dilated cardiomyopathy even under a left ventricular assist device: a safety and feasibility study. *J Surg Today.* (2018) 48:200–10. doi: 10.1007/s00318-017-1571-1

119. Cypriano DS, ‘Reprogrammed’ stem cells approved to mend human hearts for the first time. *Nature.* (2018). 557:619–620. doi: 10.1038/d41586-018-05278-8

120. Zhang J. Engineered tissue patch for cardiac tissue care. *Curr Treat Options Cardiovasc Med.* (2015). 17:399. doi: 10.1007/s11936-015-0399-5

121. Renniks M, Papageorgiou AP, Fragkogiannis NG, Heymans S. Myocardial extracellular matrix: an ever-changing and diverse entity. *Circ Res.* (2014) 114:782–88. doi: 10.1161/CIRCRESAHA.114.305353

122. Nielsen SH, Mouton AJ, DeLeon-Pennell KY, Genovese F, Karsdal M, Lindsey ML. Understanding cardiac extracellular matrix remodelling to develop biomarkers of myocardial infarction outcomes. *Matrix Biol.* (2019) 75-76:43–57. doi: 10.1016/j.matbio.2017.12.001

123. Theocharis AD, Skandalis SS, Gialieli C, Karamanos NK. Extracellular matrix structure. *Adv Drug Deliv Rev.* (2016) 97:4–27. doi: 10.1016/j.addr.2015.11.001

124. Leor J, Landa N, Cohen S. Renovation of the injured heart with myocardial tissue engineering. *Expert Rev Cardiovasc Ther.* (2006) 4:239–52. doi: 10.1586/14797972.4.3.239
144. Gaetani R, Doeverdans PA, Metz CH, Alblas J, Messina E, Giacomello A, et al. Cardiac tissue engineering using tissue printing technology and human cardiac progenitor cells. *Biomaterials.* (2012) 33:1782–90. doi: 10.1016/j.biomaterials.2011.11.003

145. Gaetani R, Feyen DA, Verhage V, Slalts R, Messina E, Christman KL, et al. Epidermal application of cardiac progenitor cells in a 3D-printed gelatin/hyaluronic acid patch preserves cardiac function after myocardial infarction. *Biomaterials.* (2015) 61:339–48. doi: 10.1016/j.biomaterials.2015.05.005

146. LaBarge W, Morales A, Pretorius D, Kahn-Krell AM, Kannappan R, Zhang J. Scaffold-Free bioprinter utilizing layer-by-layer printing of cellular spheroids. *Micromachines.* (2019) 10:570. doi: 10.3390/mi10090570

147. Ajeti V, Lien CH, Chen SJ, Su PJ, Squirell JM, Molinaro KH, et al. Image-inspired 3D multiphoton excited fabrication of extracellular matrix structures by modulated raster scanning. *Opt Express.* (2013) 21:25346–5. doi: 10.1364/OE.21.025346

148. Kupfer ME, Lin WH, Ravikumar A, Pretorius D, Kahn-Krell AM, Kannappan R, Zhang J. Scaffold-Free bioprinter utilizing layer-by-layer printing of cellular spheroids. *Micromachines.* (2019) 10:570. doi: 10.3390/mi10090570

149. Marbán E. The secret life of exosomes: what bees can teach Us about next-generation therapeutics. *J Am Coll Cardiol.* (2018). 71:193–200. doi: 10.1016/j.jacc.2017.11.013

150. Merino-González C, Zuluaga FA, Escudero C, Ormazabal V, Reyes C, Nova-Weiss S, et al. Image-inspired 3D multiphoton excited fabrication of extracellular matrix structures by modulated raster scanning. *Opt Express.* (2013) 21:25346–5. doi: 10.1364/OE.21.025346

151. Bar A, Cohen S. Inducing endogenous cardiac regeneration: can biomaterials connect the dots? *Front Biotechnol.* (2020) 8:126. doi: 10.3389/fbioe.2020.00127

152. Huang K, Ozpinar EW, Su T, Tang J, Shen D, Qiao L, et al. Fabrication of functional three-dimensional tissues by stacking cell sheets in vitro. *Nat Protoc.* (2012) 7:850–8. doi: 10.1038/nprot.2012.027

153. Kolesky DB, Truby RL, Gladman AS, Busbee TA, Homan KA, Lewis JA. 3D printing of micro-vascular networks: a review. *Acta Biomater.* (2015) 61:339–48. doi: 10.1016/j.actbio.2015.05.006

154. Fleischer S, Shapiro A, Feiner R, Dvir T. Modular assembly of thick vascular microtissues using parallel channel perfusion. *Biomaterials.* (2016) 72:24. doi: 10.1016/j.biomaterials.2015.05.006

155. Fleischer S, Shapiro A, Feiner R, Dvir T. Modular assembly of thick vascular microtissues using parallel channel perfusion. *Biomaterials.* (2016) 72:24. doi: 10.1016/j.biomaterials.2015.05.006

156. Fleischer S, Shapiro A, Feiner R, Dvir T. Modular assembly of thick vascular microtissues using parallel channel perfusion. *Biomaterials.* (2016) 72:24. doi: 10.1016/j.biomaterials.2015.05.006

157. Fleischer S, Shapiro A, Feiner R, Dvir T. Modular assembly of thick vascular microtissues using parallel channel perfusion. *Biomaterials.* (2016) 72:24. doi: 10.1016/j.biomaterials.2015.05.006

158. Fleischer S, Shapiro A, Feiner R, Dvir T. Modular assembly of thick vascular microtissues using parallel channel perfusion. *Biomaterials.* (2016) 72:24. doi: 10.1016/j.biomaterials.2015.05.006

159. Fleischer S, Shapiro A, Feiner R, Dvir T. Modular assembly of thick vascular microtissues using parallel channel perfusion. *Biomaterials.* (2016) 72:24. doi: 10.1016/j.biomaterials.2015.05.006

160. Fleischer S, Shapiro A, Feiner R, Dvir T. Modular assembly of thick vascular microtissues using parallel channel perfusion. *Biomaterials.* (2016) 72:24. doi: 10.1016/j.biomaterials.2015.05.006

161. Fleischer S, Shapiro A, Feiner R, Dvir T. Modular assembly of thick vascular microtissues using parallel channel perfusion. *Biomaterials.* (2016) 72:24. doi: 10.1016/j.biomaterials.2015.05.006
of hydrogel cell carriers. *Tissue Eng Part A.* (2012) 18:806–15. doi: 10.1089/ten.tea.2011.0391

183. Tang XL, Nakamura S, Li Q, Wysoczynski M, Gumpert AM, Wu WJ, et al. Repeated Administrations of Cardiac Progenitor Cells Are Superior to a Single Administration of an Equivalent Cumulative Dose. *J Am Heart Assoc.* (2018) 7(6). doi: 10.1161/JAHA.117.007400

184. Desgros M, Menasché P. Clinical Translation of Pluripotent Stem Cell Therapies: Challenges and Considerations. *Cell Stem Cell.* (2019) 25:594–606. doi: 10.1016/j.stem.2019.01.001

185. Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, Schulman SP, et al., Reisman MA, Schaer GL, Sherman W A. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. *J Am Coll Cardiol.* (2009) 54:2277–86. doi: 10.1016/j.jacc.2009.06.055

186. García JR, Campbell PE, Kumar G, Langberg JF, Cesar L, Wang A, et al. A Minimally Invasive, Translational Method to Deliver Hydrogels to the Heart Through the Pericardial Space. *JACC Basic Transl Sci.* (2017) 2:601–609. doi: 10.1016/j.jacbts.2017.06.003

187. Pena B, Laughter M, Jett S, Rowland TJ, B.M. Taylor RG, Mestroni L, et al. Injectable Hydrogels for Cardiac Therapy. *Mol Biochem. Pa.* (2018) e1800079. doi: 10.1161/MB.180.00079

188. Wu T, Cui C, Huang Y, Liu Y, Fan C, Hanzel U, et al. Cardiomyocyte transplantation into the infarcted pig heart but induce ventricular tachyarrhythmias. *Circ Res.* (2015) 116:1204–19. doi: 10.1161/CIRCRESAHA.114.310194

189. Zimmermann WH. Translating myocardial remuscularization. *Circ Res.* (2017) 120:278–81. doi: 10.1161/CIRCRESAHA.116.3110194

190. Zhu W, Zhao M, Mattappally S, Shen C, Zhang J. CCND2 overexpression enhances the regenerative potency of human induced pluripotent stem cell-derived cardiomyocytes: remuscularization of injured ventricle. *Circ Res.* (2018) 122:88–96. doi: 10.1161/CIRCRESAHA.117.315094

191. Serpooshan V, Zhao M, Seto T, Wang L, Wei Y, Krishnamurthy P, Walcott GP, Menasché P, et al. Superaligned carbon nanotubes guide oriented cell growth and promote electrophysiological homogeneity for synthetic cardiac tissues. *Adv Mater.* (2017) 29:1702713. doi: 10.1002/adma.201702713

192. Wang L, Wu Y, Hu T, Guo B, Ma PX. Electropump conductive nanofibrous scaffolds for engineering cardiac tissue and 3D bioactuators. *Acta Biomater.* (2017) 59:68–78. doi: 10.1016/j.actbio.2017.06.036

193. Naccarelli GD, Heiss IG, Paradies M, et al. Myocardial regeneration: ongoing clinical translation. *Nat Rev Cardiol.* (2017) 14:266–86. doi: 10.1038/nrcardio.2017.92

194. Wu T, Cui C, Huang Y, Liu Y, Fan C, Hanzel U, et al. Cardiomyocyte transplantation into the infarcted pig heart but induce ventricular tachyarrhythmias. *Circ Res.* (2015) 116:1204–19. doi: 10.1161/CIRCRESAHA.114.310194

195. Zimmermann WH. Remuscularization of the failing heart. *J Physiol.* (2017) 595:3685–90. doi: 10.1113/jp273098

196. Malat G, Cülik C. The ABCs of immunosuppression: a primer for primary care physicians. *Med Clin North Am.* (2016) 100:505–18. doi: 10.1016/j.mcna.2016.01.003

197. Pan Y, Leveson-Gower DB, de Almeida PE, Pierini A, Baker J, Florek M, et al. Engraftment of embryonic stem cells and differentiated progeny by host conditioning with total lymphoid irradiation and regulatory T cells. *Cell Rep.* (2015) 17:1973–82. doi: 10.1016/j.celrep.2015.02.050

198. Braza MS, M. van Leent MT, Lameijer M, Sanchez-Gaylan BL, Arts RJW, Pérez-Medina C, et al. Inhibiting inflammation with myeloid cell-specific nanobiologics promotes organ transplant acceptance. *Immunity.* (2018) 49:819–28.e6. doi: 10.1016/j.immuni.2018.09.008

199. Hsu PD, Lander ES, Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. *Cell.* (2014) 157:1262–78. doi: 10.1016/j.cell.2014.05.010

200. Kim H, Kim JS. A guide to genome engineering with programmable nucleases. *Nat Rev Genet.* (2014) 15:321–4. doi: 10.1038/nrg3686

201. Mattappally S, Pawlik KM, Fast VG, Zumaquero E, Lund FE, Randall TD, et al. Human leukocyte antigen class I and II knockout human induced pluripotent stem cell-derived cells: universal donor for cell therapy. *J Am Heart Assoc.* (2017) 6:010239. doi: 10.1161/JAHA.116.010239

202. Deuse T, Hu X, Gravina A, Wang D, Tedisavoli G, de C, et al. Targeted disruption of HLA genes via CRISPR-Cas9 generates iPSCs with improved immune rejection in fully immunocompetent allogeneic recipients. *Nat Biotechnol.* (2019) 37:252. doi: 10.1038/s41587-019-0016-3

203. Xu H, Wang B, Ono M, Kagita A, Fujii K, Sasakawa N, et al. Hypoinmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients. *Nat Biotechnol.* (2019) 37:252. doi: 10.1038/s41587-019-0016-3

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Copyright © 2021 Wang, Serpooshan and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use distribution or reproduction is permitted which does not comply with these terms.